ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States

Overview

About this study

The purpose of this study is to collect data on the early use of ADSTILADRIN. Data will be collected from participants, caregivers and prescribing physicians in a real-world setting.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Prescribed and scheduled treatment with ADSTILADRIN per physician discretion or
received the first instillation of ADSTILADRIN per physician discretion after 5
September 2023 but prior to site activation

- Signed and dated ICF.

- Age 18 years or older at day ICF is signed.

Exclusion Criteria:

- Currently enrolled in a clinical trial.

- Participants who have previously been treated with ADSTILADRIN in the context of a
clinical trial

- Participant is pregnant or breastfeeding.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/19/23. Questions regarding updates should be directed to the study team contact

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Stephen Boorjian, M.D.

Open for enrollment

Contact information:

Wendy Sundt CCRP

(507) 293-0303

Sundt.Wendy@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Timothy Lyon, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mark Tyson, M.D., M.P.H.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available